Arbutus Biopharma Reports Executive Changes, Compensation on Dec 31

Ticker: ABUS · Form: 8-K · Filed: 2024-01-04T00:00:00.000Z

Sentiment: neutral

Topics: executive-changes, compensation, corporate-governance

TL;DR

**Arbutus Biopharma just reported executive changes and compensation details from Dec 31, 2023.**

AI Summary

Arbutus Biopharma Corp filed an 8-K on January 4, 2024, reporting an event on December 31, 2023, related to changes in directors or officers and their compensation. This filing indicates potential shifts in leadership or executive pay structures, which could impact the company's strategic direction and financial performance. Investors should pay attention to these changes as they can signal future operational adjustments or a new focus for the company, potentially affecting stock valuation.

Why It Matters

Changes in executive leadership or compensation can signal strategic shifts or financial health, directly influencing investor confidence and the company's future direction.

Risk Assessment

Risk Level: medium — Changes in executive compensation or leadership can introduce uncertainty regarding future company strategy and performance, posing a medium risk.

Analyst Insight

An investor should monitor subsequent filings or company announcements for specific details on the executive changes and compensation arrangements to assess their potential impact on the company's strategy and financial outlook.

Key Players & Entities

Forward-Looking Statements

FAQ

What was the specific date of the earliest event reported in this 8-K filing by Arbutus Biopharma Corp?

The earliest event reported in this 8-K filing by Arbutus Biopharma Corp occurred on December 31, 2023.

When was this 8-K filing submitted to the SEC?

This 8-K filing was submitted to the SEC on January 4, 2024.

What items are specifically mentioned in the 'ITEM INFORMATION' section of this 8-K?

The 'ITEM INFORMATION' section mentions 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers'.

What is the business address of Arbutus Biopharma Corp as stated in the filing?

The business address of Arbutus Biopharma Corp is 701 Veterans Circle, Warminster, Pennsylvania, 18974.

What is the Commission File Number for Arbutus Biopharma Corp?

The Commission File Number for Arbutus Biopharma Corp is 001-34949.

From the Filing

0001447028-24-000006.txt : 20240104 0001447028-24-000006.hdr.sgml : 20240104 20240104160910 ACCESSION NUMBER: 0001447028-24-000006 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20231231 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240104 DATE AS OF CHANGE: 20240104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arbutus Biopharma Corp CENTRAL INDEX KEY: 0001447028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 980597776 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34949 FILM NUMBER: 24511902 BUSINESS ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 BUSINESS PHONE: 604-419-3200 MAIL ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS Corp DATE OF NAME CHANGE: 20110607 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20081003 8-K 1 abus-20231231.htm 8-K abus-20231231 FALSE 0001447028 701 Veterans Circle Warminster Pennsylvania 0001447028 2023-12-31 2023-12-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM  8-K   CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported):  December 31, 2023      Arbutus Biopharma Corp oration (Exact name of registrant as specified in its charter)   British Columbia, Canada   001-34949   98-0597776 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)   701 Veterans Circle Warminster , Pennsylvania   18974 (Address of principal executive offices)   (Zip Code)   ( 267 ) 469-0914 Registrant’s telephone number, including area code     (Former name or former address, if changed since last report.)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Shares, without par value   ABUS   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  Emerging growth company  ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    o Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. William H. Collier Separation and Consulting Agreements As previously disclosed, William H. Collier retired as Chi

View on Read The Filing